Arix Bioscience co-leads $31 million Series A financing for new portfolio companySorriso Pharmaceuticals Arix announces a new portfolio company, Sorriso, with a 26% ownership stakeSeries A proceeds will enable Sorriso Pharmaceuticals to advance its lead programme, a treatment for IBD, into clinical trialsArix M.
Subscription Notification
We have noticed that there is an issue with your subscription billing details. Please update your billing details here
Please update your billing information
The subscription details associated with this account need to be updated. Please update your billing details here to continue enjoying your subscription.
Your subscription will end shortly
Please update your billing details here to continue enjoying your access to the most informative and considered journalism in the UK.
UTILITY Therapeutics Joins Antimicrobials Working Group
News provided by
Share this article
Share this article
WASHINGTON, Feb. 17, 2021 /PRNewswire/ The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG s membership to 13 antimicrobial drug companies.
UTILITY is focused on developing and commercializing antibiotics in the United States to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused b
Antimicrobials Working Group Announces Updates to Leadership Team
News provided by
Share this article
Share this article
WASHINGTON, Jan. 27, 2021 /PRNewswire/ The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairperson, Ciara Kennedy, Ph.D., President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc. Dr. Kennedy replaces Evan Loh, M.D., Chief Executive Officer of Paratek Pharmaceuticals, Inc., who has completed his two-year term as Chairman of AWG. Dr. Loh will remain on the AWG Executive Committee. AWG also announced that Executive Committee member Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics, has been appointed Vice Chair.